Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?

Key Takeaways Ironwood's share of Linzess U.S. net profit declined 15% year over year to $289.3M in 2025.IRWD noted that rebate adjustments and Medicare Part D pricing pressure caused the sales dip, not weak demand.Ironwood expects 2026 revenues to be in the band of $450M-$475M as Linzess sales rebound.Ironwood Pharmaceuticals’ (IRWD) sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged seven y ...